Authors take: Many pharmaceutical companies are rushing to position themselves to profit from treating a tsunami of cancers that they are all expecting to hit starting in 2025…. View More
Johnson & Johnson to Acquire $2 Billion Drug Developer “Ambrx Biopharma” to Treat Turbo Cancers with Same Tech as Pfizer’s $43 Billion Seagen Acquisition
